Oncology | Lakes | Te Whatu Ora

Medical Oncology Clinical Trials - Breast: PantoCIN

Breast: PantoCIN

Pantoprazole Prophylaxis Against Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) for Patients Receiving Breast Cancer Chemotherapy

This study is currently recruiting participants.

Primary Objective: This phase II, randomised double-blind, placebo controlled, crossover study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer. Delayed nausea, and occasionally vomiting, can occur after breast cancer chemotherapy, affecting quality of life. A potential cause of these delayed side effects is that the chemotherapy may cause stomach irritation. Pantoprazole is commonly used to treat stomach irritation by reducing stomach acid, which may in turn improve nausea and/or vomiting.

Principal Investigator: Prashanth Hari Dass

Research Coordinators: Karen and Paula

Trial Website: https://clinicaltrials.gov/ct2/show/NCT03948477

 


https://www.healthpoint.co.nz/public/oncology/oncology-lakes-te-whatu-ora/